Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration
By Ben Glickman
Shares of Nurix Therapeutics rose Tuesday after the company said it had extended its strategic collaboration with Sanofi.
The stock was up 19% to $16.42 in afternoon trading, reaching its highest intraday level since September 2022. Shares have risen about 55% since the start of the year.
The biopharmaceutical company said that it and Sanofi are looking to nominate a development candidate from the program within the first year of the extended term.
The research program is studying STAT6, a key drug target for certain types of inflammation. The program uses Nurix's platform to identify new compounds that use certain enzymes to affect drug targets.
Under the agreement between the two companies, Sanofi has an option to license drug candidates resulting from the collaboration. Nurix has the option to co-develop and co-promote future products in the U.S. for certain programs.
The deal has been in place since December 2019.
Nurix also on Tuesday said it had presented its findings of clinical responses in the brain for one of its drug candidates, NX-5948, at a conference. Chief Scientific Officer Gwenn Hansen said in a statement that the results suggested a potential role for the compound in the treatment of B-cell lymphomas and some forms of lymphocytic leukemia.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 09, 2024 13:57 ET (17:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom